Achieve Life Sciences, Inc. (ACHV)

Achieve Life Sciences, Inc. is trading at $8.20, up 9.04% on the session. The 50 day average sits at $6.10 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 75.1, which reads as overbought, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $5.91 with resistance near $7.60, so that band frames the current range. Average daily movement is roughly $0.38, or about 4.6% of the share price, which is what any stop placement has to allow for. The overall health score of 69 out of 100 combines a trend score of 75, momentum of 84 and a risk score of 40.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.